Pull to refresh
Logo
Vaxcyte's pneumococcal vaccine meets all key trial goals, shares surge

Vaxcyte's pneumococcal vaccine meets all key trial goals, shares surge

New Capabilities

VAX-31 matched Prevnar 20 and Capvaxive on nearly all shared strains in the first Phase 3 trial; two more trials and a 2028 filing remain

2 days ago: VAX-31 meets all primary endpoints in OPUS-1

Overview

Updated 47 minutes ago

Vaxcyte said Monday its experimental pneumococcal vaccine met every primary goal in the first of three late-stage trials. VAX-31, which targets 31 strains of the bacteria behind pneumonia and meningitis, matched Pfizer's Prevnar 20 and Merck's Capvaxive on nearly all shared strains, beat both on three strains only it covers, and sent shares up roughly 50% to push the company's market value past $12 billion.

The results beat Wall Street expectations. Analysts at Mizuho called them a near best-case outcome with best-in-class potential in an adult pneumococcal vaccine market worth about $8 billion a year. Two more Phase 3 trials are due in the first half of 2027, with a regulatory filing planned for 2028.

Why it matters

If VAX-31 wins approval, it could redirect billions in annual vaccine sales from Pfizer and Merck and set a new coverage standard for pneumococcal protection.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

31
Bacterial strains covered by VAX-31
Compared with 20 for Prevnar 20 and 21 for Capvaxive.
20 of 20
Shared strains meeting noninferiority vs Prevnar 20
VAX-31 matched Pfizer's shot on all 20 shared serotypes at the stricter threshold.
17 of 19
Shared strains meeting noninferiority vs Capvaxive
Two strains met a looser historical threshold (0.5) instead of the stricter 0.667.
$12B
Vaxcyte market value after results
Shares climbed about 50% in early trading Monday.
$8B
Annual adult pneumococcal vaccine market
Analyst estimate cited by Mizuho's Salim Syed.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

People Involved

Organizations Involved

Timeline

May 2026 October 2026

3 events Latest: 2 days ago
  1. VAX-31 meets all primary endpoints in OPUS-1

    Latest Clinical trial

    Vaxcyte announces positive topline results; shares surge roughly 50% and market value passes $12 billion.

  2. Analyst flags trial as must-play catalyst

    Market analysis

    Mizuho's Salim Syed calls the OPUS-1 readout a 'must-play catalyst' for biotech investors.

  3. Vaxcyte signals possible misses on some strains

    Statement

    Executives suggested VAX-31 might not match Capvaxive on all strains, weakening investor expectations.

Scenarios

1

VAX-31 clears final trials, FDA filing lands in 2028

Likely Resolves by Q2 2028

Discussed by: Mizuho's Salim Syed; Leerink Partners' David Risinger

OPUS-2 and OPUS-3 confirm the OPUS-1 safety and immunogenicity profile. Vaxcyte completes a manufacturing consistency study and submits its Biologics License Application to the U.S. Food and Drug Administration in the first half of 2028, with approval possible in 2029. Analysts said the OPUS-1 data 'raise the bar' for the vaccine class.

2

A remaining trial stumbles, delaying approval

Possible Resolves by Q2 2027

Discussed by: Wall Street analysts tracking VAX-31 after Vaxcyte's May comments about possible misses

OPUS-2 or OPUS-3 shows VAX-31 failing a prespecified primary endpoint, such as missing noninferiority against Capvaxive on multiple serotypes. Vaxcyte needs extra studies or a formulation change, pushing any filing past 2028. The May skepticism showed investors are watching for exactly this.

3

A competitor answers with a wider vaccine

Possible Resolves by End of 2028

Discussed by: Industry analysts tracking the pneumococcal market

Pfizer or Merck accelerates a next-generation pneumococcal candidate covering more serotypes than today's shots, blunting VAX-31's coverage advantage before it can gain share. The market fragments and price competition builds as several broad vaccines compete.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

2000–2010

Prevnar 7 to Prevnar 13 (2000–2010)

Wyeth launched Prevnar 7, the first pneumococcal conjugate vaccine, in 2000. Ten years later it rolled out Prevnar 13, covering 13 serotypes instead of 7. Pfizer, which bought Wyeth in 2009, turned the franchise into a multibillion-dollar seller.

Then

Prevnar 13 captured nearly the entire pediatric and adult pneumococcal vaccine market.

Now

The move established broader serotype coverage as the central competitive lever in pneumococcal vaccines.

Why this matters now

Vaxcyte is extending that logic: VAX-31 covers 31 serotypes versus 20 for Prevnar 20 and 21 for Capvaxive.

2006–2016

Gardasil vs Cervarix, HPV vaccine race (2006–2016)

Merck's Gardasil, approved in 2006, and GSK's Cervarix, approved in 2009, competed for the HPV vaccine market. Gardasil kept expanding its label, including coverage for boys, while Cervarix never matched its reach.

Then

Cervarix held some European market share but lost ground in the United States.

Now

GSK withdrew Cervarix from the U.S. market in 2016, leaving Gardasil dominant. The episode shows how hard it is for a challenger to unseat an entrenched vaccine incumbent.

Why this matters now

Vaxcyte faces the same dynamic: Prevnar 20 and Capvaxive are established, and VAX-31 must convert a coverage advantage into real market share.

Sources

(5)